Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-25, Stock:ABBV, The news for the past five days is as follows:
2019-06-18: NEWS1: Bayer to Invest 5 Billion Euros in Weedkiller Research.
2019-06-19: NEWS1: What to Look for in AbbVie’s Oncology Portfolio in 2019.NEWS2: How Is AbbVie Positioned in June?.NEWS3: AbbVie or Allergan: Which Is a Better Pick in June?.NEWS4: Is Abbott Laboratories a Buy?.NEWS5: Is Abbott Laboratories a Buy?.NEWS6: How Do Rate Cuts Impact Healthcare Stocks?.
2019-06-20: NEWS1: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS2: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS3: AbbVie Declares Quarterly Dividend.NEWS4: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS5: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS6: These New Product Launches Could Partially Offset Humira’s Losses.
2019-06-21: NEWS1: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS2: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS3: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS4: Notable Friday Option Activity: ABBV, VLO, KNX.NEWS5: Notable Friday Option Activity: ABBV, VLO, KNX.NEWS6: Top Ranked Income Stocks to Buy for June 21st.NEWS7: Daily Dividend Report: WASH, MDT, CL, ABBV, UDR.NEWS8: Daily Dividend Report: WASH, MDT, CL, ABBV, UDR.NEWS9: Sanofi/Regeneron's Asthma Candidate Meets Goal in Study.NEWS10: Sanofi/Regeneron's Asthma Candidate Meets Goal in Study.NEWS11: Top Ranked Income Stocks to Buy for June 21st.NEWS12: Sanofi/Regeneron's Asthma Candidate Meets Goal in Study.
2019-06-24: NEWS1: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS2: Forget Bargain Hunting: Tap 5 Stocks With Rising P/E.NEWS3: FDA lifts  hold on one of AbbVie's trials of venetoclax.NEWS4: AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality.NEWS5: Forget Bargain Hunting: Tap 5 Stocks With Rising P/E.

Answer: Decrease